GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (NAS:YTEN) » Definitions » Piotroski F-Score
中文

Yield10 Bioscience (Yield10 Bioscience) Piotroski F-Score : 1 (As of Apr. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yield10 Bioscience has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Yield10 Bioscience's Piotroski F-Score or its related term are showing as below:

YTEN' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 1

During the past 13 years, the highest Piotroski F-Score of Yield10 Bioscience was 4. The lowest was 1. And the median was 3.


Yield10 Bioscience Piotroski F-Score Historical Data

The historical data trend for Yield10 Bioscience's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience Piotroski F-Score Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 3.00 2.00 1.00

Yield10 Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 1.00

Competitive Comparison of Yield10 Bioscience's Piotroski F-Score

For the Agricultural Inputs subindustry, Yield10 Bioscience's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience's Piotroski F-Score Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -3.782 + -3.681 + -3.726 + -3.266 = $-14.46 Mil.
Cash Flow from Operations was -2.667 + -3.079 + -2.611 + -1.711 = $-10.07 Mil.
Revenue was 0.06 + 0 + 0 + 0.06 = $0.12 Mil.
Gross Profit was 0.06 + 0 + 0 + 0.06 = $0.12 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(8.085 + 5.334 + 5.87 + 6.042 + 3.907) / 5 = $5.8476 Mil.
Total Assets at the begining of this year (Dec22) was $8.09 Mil.
Long-Term Debt & Capital Lease Obligation was $1.53 Mil.
Total Current Assets was $1.40 Mil.
Total Current Liabilities was $4.87 Mil.
Net Income was -3.331 + -3.443 + -3.489 + -3.303 = $-13.57 Mil.

Revenue was 0.149 + 0.103 + 0 + 0.45 = $0.70 Mil.
Gross Profit was 0.149 + 0.103 + 0 + 0.45 = $0.70 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(20.415 + 17.104 + 14.273 + 11.272 + 8.085) / 5 = $14.2298 Mil.
Total Assets at the begining of last year (Dec21) was $20.42 Mil.
Long-Term Debt & Capital Lease Obligation was $2.08 Mil.
Total Current Assets was $5.02 Mil.
Total Current Liabilities was $1.61 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yield10 Bioscience's current Net Income (TTM) was -14.46. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yield10 Bioscience's current Cash Flow from Operations (TTM) was -10.07. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-14.455/8.085
=-1.78787879

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-13.566/20.415
=-0.66451139

Yield10 Bioscience's return on assets of this year was -1.78787879. Yield10 Bioscience's return on assets of last year was -0.66451139. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Yield10 Bioscience's current Net Income (TTM) was -14.46. Yield10 Bioscience's current Cash Flow from Operations (TTM) was -10.07. ==> -10.07 > -14.46 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.525/5.8476
=0.26079075

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.075/14.2298
=0.14582074

Yield10 Bioscience's gearing of this year was 0.26079075. Yield10 Bioscience's gearing of last year was 0.14582074. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=1.4/4.865
=0.28776978

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=5.018/1.61
=3.11677019

Yield10 Bioscience's current ratio of this year was 0.28776978. Yield10 Bioscience's current ratio of last year was 3.11677019. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Yield10 Bioscience's number of shares in issue this year was 12.032. Yield10 Bioscience's number of shares in issue last year was 4.944. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.12/0.12
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.702/0.702
=1

Yield10 Bioscience's gross margin of this year was 1. Yield10 Bioscience's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.12/8.085
=0.0148423

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.702/20.415
=0.03438648

Yield10 Bioscience's asset turnover of this year was 0.0148423. Yield10 Bioscience's asset turnover of last year was 0.03438648. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yield10 Bioscience has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Yield10 Bioscience  (NAS:YTEN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Yield10 Bioscience Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience (Yield10 Bioscience) Business Description

Traded in Other Exchanges
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038

Yield10 Bioscience (Yield10 Bioscience) Headlines

From GuruFocus